MICHAEL R MIGDEN to Adult
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Adult.
Connection Strength
0.223
-
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 08; 9(8).
Score: 0.030
-
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020 06; 182(6):1369-1378.
Score: 0.027
-
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351.
Score: 0.024
-
Surgical site identification with personal digital device: A prospective pilot study. J Am Acad Dermatol. 2018 Sep; 79(3):520-524.
Score: 0.024
-
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28.
Score: 0.020
-
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer. 2024 03 11; 12(3).
Score: 0.009
-
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024 Feb; 35(2):221-228.
Score: 0.009
-
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857.
Score: 0.007
-
Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
Score: 0.007
-
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1).
Score: 0.007
-
Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
Score: 0.007
-
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091.
Score: 0.006
-
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381.
Score: 0.006
-
Multiple eccrine spiradenomas in a zosteriform pattern. Dermatol Online J. 2017 Aug 15; 23(8).
Score: 0.006
-
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 09 01; 11(1):120.
Score: 0.005
-
Phototherapeutic keratectomy for corneal scars. Ophthalmic Surg Lasers. 1996 May; 27(5 Suppl):S503-7.
Score: 0.005
-
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5.
Score: 0.005
-
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8.
Score: 0.005
-
Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2.
Score: 0.005
-
Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis. J Biomed Opt. 2014; 19(11):117003.
Score: 0.004
-
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9.
Score: 0.004